China Resources subsidiary gets approval for 3 bn yuan medium-term notes

China Resources Pharmaceutical Group Limited announced that its non-wholly-owned subsidiary, CR Pharmaceutical Commercial, has received a notice of acceptance of registration from the National Association of Financial Market Institutional Investors. This notice allows CR Pharmaceutical Commercial to issue medium-term notes in the People's Republic of China.

The registration is effective for a two-year period from its issue date, during which CR Pharmaceutical Commercial can issue notes totaling 3 bn yuan in tranches. The proceeds from these issuances are expected to be utilized for the repayment of interest-bearing debt owed by CR Pharmaceutical Commercial or its subsidiaries. The company will provide further updates as the proposed issuance progresses.

Shareholders and potential investors are advised to exercise caution as the issuance may or may not proceed.